Acquity csh c18

Manufactured by Waters Corporation

Sourced in United States

The Acquity CSH C18 is a reversed-phase chromatography column designed for high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC) applications. It features a hybrid silica-based stationary phase that provides high-efficiency separation of a wide range of analytes, including polar and non-polar compounds.

Automatically generated - may contain errors

Lab products found in correlation

Acquity beh c18, by Waters Corporation (2 mentions) Oasis mcx, by Waters Corporation (1 mentions) Xevo tq s triple quadrupole mass spectrometer, by Waters Corporation (1 mentions) 1290 infinity uhplc system, by Agilent Technologies (1 mentions) Masshunter software, by Agilent Technologies (1 mentions) Solid silica spheres, by Thermo Fisher Scientific (1 mentions) Solid borosilicate spheres, by Thermo Fisher Scientific (1 mentions) Jupiter proteo, by Phenomenex (1 mentions) Chromeleon 7, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

ACQUITY UPLC CSH C18 column (51 citations) CSH C18 (32 citations) Acquity CSH C18 column (30 citations) Acquity UPLC CSH C18 (21 citations) ACQUITY UPLC Peptide CSH C18 Column (9 citations) ACQUITY UPLC® CSHTM C18 column (6 citations) Acquity CSH C18 1.7 μm 1 × 150 mm column (4 citations) Acquity Premier CSH C18 column (4 citations) Acquity UPLC CSH C18 VanGuard precolumn (4 citations) ACQUITY UPLC CSH C18 1.7 μm (3 citations)

10 protocols using acquity csh c18

LC-MS Analysis of Organic Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

EXAMPLE 7

LC-MS Retention Time 1.053 min

LC:Agilent 1290

ESI/APCI MS:Agilent 6130

Column: Waters Acquity CSH C18 1.7 um, 2.1×50 mm

Solvent: H₂O:CH₃CN(0.1% Formic acid)

Gradient: 0.8 mL/min, 0 min(95:5)→1.2 min(50:50)

1.0 mL/min, →1.38 min(3:97)

MS (+): 1195 [M+H]⁺.

LC-MS Retention Time 1.068 min

LC:Agilent 1290

ESI/APCI MS:Agilent 6130

Column: Waters Acquity CSH C18 1.7 um, 2.1×50 mm

Solvent: H₂O:CH3CN(0.1% Formic acid)

Gradient: 0.8 mL/min, 0 min(95:5)→1.2 min(50:50)

1.0 mL/min, →1.38 min(3:97)

MS (+): 1095 [M+H]⁺.

US09932331B2. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl (2018-04-03). TAISHO PHARMACEUTICAL CO., LTD [JP]. Inventors: Shoichi Kuroda [JP], Kenichi Kawabe [JP], Yasunobu Ushiki [JP], Hiroshi Ohta [JP], Fumito Uneuchi [JP], Tsuyoshi Shibata [JP], Hideaki Tabuse [JP], Eiji Munetomo [JP], Sumi Chonan [JP].

+ Open protocol

+ Expand

Quantifying Angiotensin Peptides in Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols

Endogenous serum concentrations of ANG I and ANG II were measured by ultra-performance liquid chromatography with tandem mass spectrometry detection, capable of measuring angiotensin peptide levels as low as 10 pg/mL (inVentiv Health Clinique, Quebec City, Quebec, Canada). Following rapid thawing of the serum, samples were stabilized with a combination of aliskiren, pepstatin A, and o-phenanthroline in acidified dimethyl sulfoxide combined with a mixture of EDTA and 4-(hydroxymercury) benzoic acid in phosphate-buffered saline. All samples were spiked with stable-isotope-labeled internal standards for ANG I and ANG II at a concentration of 50 pg/mL. Following protein precipitation using acetonitrile with 1% formic acid and solid-phase extraction (Oasis MCX; Waters Corporation, Milford, MA, USA) of the supernatant, samples underwent liquid chromatography-tandem mass spectrometry analysis using a reverse-phase analytical column (Acquity CSH C18; Waters Corporation) operating in line with an XEVO TQ-S triple quadrupole mass spectrometer (Waters Corporation) in multiple reaction monitoring. The sum of the signal from three different mass transitions per peptide was measured, and angiotensin concentrations were calculated by relating the ratio of peptide signal to internal standard signal.

Bellomo R., Wunderink R.G., Szerlip H., English S.W., Busse L.W., Deane A.M., Khanna A.K., McCurdy M.T., Ostermann M., Young P.J., Handisides D.R., Chawla L.S., Tidmarsh G.F, & Albertson T.E. (2020). Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Critical Care, 24, 43.

+ Open protocol

+ Expand

HPLC Conditions for In-Vitro Drug Release

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 10

Suitable HPLC Conditions for Measuring In-Vitro Release

Instrument Parameters

Flow rate0.300mL/min

Sample loop20μL

Injection volume5μL

Autosampler Temperature5°C.

Column Temperature30°C.

Detector wavelength240nm

Sampling rate20points/second

Run time8min

Pump Gradient Program

MobileMobileGradient

TimePhase A (%)Phase B (%)Slope

0.085156

4.080206

5.050506

6.015856

6.185156

885156

Mobile Phase-A: 0.10% TFA in water: Fill a 2-L glass media bottle with 2 L purified water. Add 2.0±0.1 mL of TFA and mix.

Mobile Phase-B: 0.08% TFA in acetonitrile: Fill a 2 L glass media bottle with 2 L acetonitrile. Add 1.6±0.1 mL of TFA and mix.

HPLC Column: Waters Acquity CSH C18, 2.1×150 mm, 3 μm (P/N 186005298)

US10577351B2. Therapeutic polymeric nanoparticles and methods of making and using same (2020-03-03). ASTRAZENECA AB [SE]. Inventors: Marianne Bernice Ashford [GB], James Martin Nolan, III [US], Eyoung Shin [US], Young-Ho Song [US], Greg Troiano [US], Hong Wang [US].

+ Open protocol

+ Expand

UHPLC-QTOF-MS Characterization of Peptides and Small Molecules

Check if the same lab product or an alternative is used in the 5 most similar protocols

The experiments relative to peptides and small molecules were performed on a UHPLC 1290 Infinity system from Agilent Technologies (Waldbronn, Germany). The binary system was equipped with two high‐pressure solvent delivery pumps, an autosampler with a flow‐through needle injector, and a thermostatic column compartment with low dispersion preheaters. The system was hyphenated to a quadrupole‐TOF high‐resolution mass spectrometer (model G6560B) from Agilent Technologies. The measured dwell volume and overall extra‐column volumes were 0.17 and 0.031 ml, respectively. Instrument control and data acquisition were performed by Mass Hunter software (Agilent Technologies). Mass spectrometry data were acquired in positive ion mode for peptides and basic compounds, and negative mode for acidic compounds. The acquisition rate was 20 spectra/s.
The chromatographic column was an Acquity CSH C18 (50 × 2.1 mm, 1.7 μm) from Waters (Milford, MA, USA). Mobile phase A was composed of H₂O + 0.1% FA, while mobile phase B contains ACN + 0.1% FA. An equilibration time of five dead times was systematically added between runs. The column temperature was 80°C for peptides with a flow rate of 2.1 ml/min. It was 30°C for small molecules with a flow rate of 0.5 ml/min.

Guillarme D., Bouvarel T., Rouvière F, & Heinisch S. (2022). A simple mathematical treatment for predicting linear solvent strength behavior in gradient elution: Application to biomolecules. Journal of Separation Science, 45(17), 3276-3285.

+ Open protocol

+ Expand

Chromatographic Analysis of Pharmaceutical Products

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 9

The products and compositions disclosed herein may be analyzed by liquid chromatography, a suitable chromatographic method using UPLC, e.g. using materials and conditions such as Waters Acquity CSH C18, 1.7 μm, 150×2.1 mm column, water with 0.1% TFA (mobile phase A), and water/ACN 70/30+0.1% TFA (mobile phase B), ranging from (4% phase A/6% phase B to 100% phase B and flushed with 4% phase A/6% phase B). Flow rate: 0.35 ml/min, Column temperature: 40° C., autosampler temperature: 4° C., injection volume: 4 μl (e.g. prepared by weighing about 10 mg of powder in a 10 ml volumetric flask and diluted to volume with water). Examples of detectors are UV (ultraviolet, UV 220 nm) and MS (mass spectrometry).

US11866406B2. Compositions of trofinetide (2024-01-09). NEUREN PHARMACEUTICALS LIMITED [NZ]. Inventors: Clive Blower [AU], Mathew Peterson [US], James Murray Shaw [AU], James Anthony Bonnar [AU], Etienne David Frank Philippe Moniotte [BE], Martin Bernard Catherine Bousmanne [BE], Cecilia Betti [BE], Karel Willy Luc Decroos [BE], Mimoun Ayoub [CH].

+ Open protocol

+ Expand

Fabrication of Capillary Columns for TASF

Check if the same lab product or an alternative is used in the 5 most similar protocols

Capillary columns used in all TASF experiments were prepared by packing either Acquity BEH C18 or Acquity CSH C18, 1.7 μm particles (Waters) into 100 or 150 μm I.D. fused-silica capillaries from Polymicro Technologies (Phoenix, AZ). Columns were fritted using an electrical arc to sinter 2 μm solid borosilicate spheres (Thermo Scientific, Fremont, CA) into the end of the column blank. Particles were slurried, 65 mg/mL, in isopropanol and sonicated for 20 minutes prior to packing using the downward slurry method. Fritted blanks were placed into an ultrahigh pressure column packing fitting adapted from that previously described [17 (link)]. A model DSF-150 pneumatic amplification pump from Haskel (Burbank, CA) was used to pack columns at 20,000 psi for 20 minutes. Acetone was used as the packing solvent. Defined length columns, ca. 4.5–6.5 cm, were packed by controlling the mass of particles loaded into the packing reservoir. The remainder of the capillary blank was packed with 8 μm solid silica spheres (Thermo) for an additional 20 minutes at 20,000 psi. The silica spheres were slurried at a concentration of 100 mg/mL in a mixture of 50:50 (v/v) isopropanol/water.

Groskreutz S.R., Horner A.R, & Weber S.G. (2015). Temperature-based on-column solute focusing in capillary liquid chromatography reduces peak broadening from precolumn dispersion and volume overload when used alone or with solvent-based focusing. Journal of chromatography. A, 1405, 133-139.

+ Open protocol

+ Expand

UHPLC Separation of API Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

All solvents were LC grade and were purchased from Sigma-Aldrich (St. Louis, MO, USA) as well as trifluoroacetic acid (TFA), tetrabutylammonium hydroxide 30-hydrate (TBAOH) (≥99.0% w/w), and tetrabutylammonium hydrogen sulfate (TBAHSO4) (≥99.0% w/w). All basic compounds, in active pharmaceutical ingredient form, were available in house from previous studies. Solutions of samples were prepared in mobile phases at a concentration of 1.0 mg/ml. Four UHPLC columns, of 100 mm L x 3.0 mm I.D., were employed: Acquity BEH C18 1.7 µm and Acquity CSH C18 1.7 µm from Waters Corporation (Milford, MA, USA), Ascentis Express C18 2.0 µm and Titan C18 1.9 µm from Supelco Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Manetto S., Mazzoccanti G., Ciogli A., Villani C, & Gasparrini F. (2020). Ultra-high performance separation of basic compounds on reversed-phase columns packed with fully/superficially porous silica and hybrid particles by using ultraviolet transparent hydrophobic cationic additives. Journal of separation science, 43(9-10).

+ Open protocol

+ Expand

Liquid Chromatography Analysis of Products

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 9

US11370755B2. Compositions of trofinetide (2022-06-28). NEUREN PHARMACEUTICALS LIMITED [NZ]. Inventors: Clive Blower [AU], Mathew Peterson [US], James Murray Shaw [AU], James Anthony Bonnar [AU], Etienne David Frank Philippe Moniotte [BE], Martin Bernard Catherine Bousmanne [BE], Cecilia Betti [BE], Karel Willy Luc Decroos [BE], Mimoun Ayoub [CH].

+ Open protocol

+ Expand

Purification and Isolation of Myxoquinones

Check if the same lab product or an alternative is used in the 5 most similar protocols

Purification of myxoquinone 739 and 825 was carried out using a gradient LC system with a Waters Acquity CSH C18 250 × 10 mm 5 µm column with the eluents H₂O + 0.1% FA as A and ACN + 0.1% FA as B, a flow rate of 5 mL/min, and the column kept at 30 °C. Further chromatographic details are described in the SI. Myxoquinone A and B were detected by UV absorption at 270 nm and purification was performed by time dependent fraction collection. After evaporation, the myxoquinones 739 and 825 were obtained from fraction as pale yellowish amorphous solids. Myxoquinones 843 and 861 were isolated by semi-preparative reverse phase chromatography with a similar setup but using a Phenomenex Jupiter Proteo 250 × 10 mm, 4 µm, 30 Å column; flow rate 6 mL/min. After evaporation, the myxoquinones 843 and 861 are obtained as pale yellowish amorphous solids. The purified compounds were dried and stored in air-tight glass vials at −20 °C.

Panter F., Popoff A., Garcia R., Krug D, & Müller R. (2022). Myxobacteria of the Cystobacterineae Suborder Are Producers of New Vitamin K2 Derived Myxoquinones. Microorganisms, 10(3), 534.

+ Open protocol

+ Expand

UHPLC Gradient Elution Chromatography

Check if the same lab product or an alternative is used in the 5 most similar protocols

A UHPLC Ultimate 3000 (Dionex Thermo Fisher Scientific, Sunnyvale, CA, USA) system consisting of a pump, degasser, autosampler, and column heater instrument was used. Data processing was performed with Chromeleon 7.0 and Chromeleon Validation ICH software (Dionex). The detector used was a charged aerosol detector (CAD)—Corona Veo Thermo Scientific. Chromatographic separation was conducted using a Waters Acquity CSH C18 150 × 2.1 mm, 1.7 µm column. The work was conducted in a gradient system (phase A using ACN and phase B: ACN:CH₂Cl₂ 40:60 v/v). The following gradient system was applied: 0–1 min 20% B, 1–17 min 100% B, 17–20 min 100% B, 20–25 min 20% B and 25–34 min 20% B, balancing columns until the initial conditions were restored. Chromatographic separation was conducted with a constant flow of the mobile phase (400 μL/min) at 30 °C. The injection volume on the column was 1 μL.

Zmysłowski A., Sitkowski J., Bus K., Michalska K, & Szterk A. (2021). Synthesis of Oxidized 3β,3′β-Disteryl Ethers and Search after High-Temperature Treatment of Sterol-Rich Samples. International Journal of Molecular Sciences, 22(19), 10421.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!